Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1977 Feb;53(616):61–65. doi: 10.1136/pgmj.53.616.61

Double-blind comparison of verapamil and practolol in the treatment of angina pectoris.

B Fagher, S Persson, S E Svensson
PMCID: PMC2496622  PMID: 406602

Abstract

In thirteen patients with coronary insufficiency and angina pectoris the therapeutic effects of verapamil, 80 mg three times/day and practolol, 100 mg three times/day, were compared and tested against placebo in a double-blind cross-over fashion. Verapamil proved to be the most efficient drug as regards attack frequency and glyceryl trinitrate consumption as well as physical working capacity, bringing about a statistically significant increase of the exercise tolerance as compared to placebo after a treatment period of four weeks. Verapamil is a good alternative to beta-blockers in the prophylactic treatment of angina. Possible modes of action of verapamil in angina pectoris are discussed. The study had to be interrupted because of the reports of side effects of practolol, explaining the small number of patients.

Full text

PDF
61

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreasen F., Boye E., Christoffersen E., Dalsgaard P., Henneberg E., Kallenbach A., Ladefoged S., Lillquist K., Mikkelsen E., Norder0 E. Assessment of verapamil in the treatment of angina pectoris. Eur J Cardiol. 1975 Apr;2(4):443–452. [PubMed] [Google Scholar]
  2. Atterhög J. H., Porjé G. Isoptin vid angina pectoris. Lakartidningen. 1966 May 25;63(21):2071–2074. [PubMed] [Google Scholar]
  3. CHRISTENSSON B., KARLEFORS T., WESTLING H. HAEMODYNAMIC EFFECTS OF NITROGLYCERIN IN PATIENTS WITH CORONARY HEART DISEASE. Br Heart J. 1965 Jul;27:511–519. doi: 10.1136/hrt.27.4.511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chatterjee S. S., Perry A. E. Salbutamol: clinical application as pressure-packed aerosol. Postgrad Med J. 1971 Mar;47(Suppl):53–55. [PubMed] [Google Scholar]
  5. Felix R. H., Ive F. A., Dahl M. G. Cutaneous and ocular reactions to practolol. Br Med J. 1974 Nov 9;4(5940):321–324. doi: 10.1136/bmj.4.5940.321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fleckenstein A., Kammermeier H., Döring H. J., Freund H. J. Zum Wirkungsmechanismus neuartiger Koronadilatatoren mit gleichzeitig Sauerstoff-einsparenden Myokard-Effekten, Prenylamin und Iproveratril. 2. Z Kreislaufforsch. 1967 Aug;56(8):839–858. [PubMed] [Google Scholar]
  7. GRANATH A. MITRAL VALVULOTOMY. A CLINICAL AND HEMODYNAMIC PRE- AND POSTOPERATIVE STUDY. Acta Med Scand. 1965;178:SUPPL 433–433:1+. [PubMed] [Google Scholar]
  8. George C. F., Nagle R. E., Pentecost B. L. Practolol in treatment of angina pectoris. A double-blind trial. Br Med J. 1970 May 16;2(5706):402–404. doi: 10.1136/bmj.2.5706.402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gibson D., Sowton E. Effects of I.C.I. 50172 in man during erect exercise. Br Med J. 1968 Jan 27;1(5586):213–215. doi: 10.1136/bmj.1.5586.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Greenblatt D. J., Koch-Weser J. Adverse reactions to beta-adrenergic receptor blocking drugs: a report from the Boston collaborative drug surveillance program. Drugs. 1974;7(1):118–129. doi: 10.2165/00003495-197407010-00008. [DOI] [PubMed] [Google Scholar]
  11. Livesley B., Catley P. F., Campbell R. C., Oram S. Double-blind evaluation of verapamil, propranolol, and isosorbide dinitrate against a placebo in the treatment of angina pectoris. Br Med J. 1973 Feb 17;1(5850):375–378. doi: 10.1136/bmj.1.5850.375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Luebs E. D., Cohen A., Zaleski E. J., Bing R. J. Effect of nitroglycerin, intensain, isoptin and papaverine on coronary blood flow in man. Measured by the coincidence counting technic and rubidium. Am J Cardiol. 1966 Apr;17(4):535–541. doi: 10.1016/0002-9149(66)90245-1. [DOI] [PubMed] [Google Scholar]
  13. MULLER O., RORVIK K. Haemodynamic consequences of coronary heart disease with observations during anginal pain and on the effect of nitroglycerine. Br Heart J. 1958 Jul;20(3):302–310. doi: 10.1136/hrt.20.3.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Miller R. R., Olson H. G., Amsterdam E. A., Mason D. T. Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy. N Engl J Med. 1975 Aug 28;293(9):416–418. doi: 10.1056/NEJM197508282930902. [DOI] [PubMed] [Google Scholar]
  15. Nayler W. G., Krikler D. Verapamil and the myocardium. Postgrad Med J. 1974 Jul;50(585):441–446. doi: 10.1136/pgmj.50.585.441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Nayler W. G., Szeto J. Effect of verapamil on contractility, oxygen utilization, and calcium exchangeability in mammalian heart muscle. Cardiovasc Res. 1972 Mar;6(2):120–128. doi: 10.1093/cvr/6.2.120. [DOI] [PubMed] [Google Scholar]
  17. Petz L. D. Immunologic reactions of humans to cephalosporins. Postgrad Med J. 1971 Feb;47(Suppl):64–69. [PubMed] [Google Scholar]
  18. Phear D. N. Verapamil in angina: a double-blind trial. Br Med J. 1968 Jun 22;2(5607):740–741. doi: 10.1136/bmj.2.5607.740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Prichard B. N. Beta-adrenergic receptor blocking drugs in angina pectoris. Drugs. 1974;7(1):55–84. doi: 10.2165/00003495-197407010-00005. [DOI] [PubMed] [Google Scholar]
  20. Robinson B. F. Relation of heart rate and systolic blood pressure to the onset of pain in angina pectoris. Circulation. 1967 Jun;35(6):1073–1083. doi: 10.1161/01.cir.35.6.1073. [DOI] [PubMed] [Google Scholar]
  21. Sandler G., Clayton G. A. Clinical evaluation of practolol, a new cardioselective beta-blocking agent in angina pectoris. Br Med J. 1970 May 16;2(5706):399–402. doi: 10.1136/bmj.2.5706.399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Sandler G., Clayton G. A., Thornicroft S. G. Clinical evaluation of verapamil in angina pectoris. Br Med J. 1968 Jul 27;3(5612):224–227. doi: 10.1136/bmj.3.5612.224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Shinebourne E., Fleming J., Hamer J. Haemodynamic responses to exercise in hypertension: place of the sympathetic nervous sustem evaluated by a new selective cardiac beta-adrenergic blocking agent ICI 50,172. Cardiovasc Res. 1968 Oct;2(4):379–383. doi: 10.1093/cvr/2.4.379. [DOI] [PubMed] [Google Scholar]
  24. Singh B. N. A fourth class of anti-dysrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function. Cardiovasc Res. 1972 Mar;6(2):109–119. doi: 10.1093/cvr/6.2.109. [DOI] [PubMed] [Google Scholar]
  25. Wright P. Untoward effects associated with practolol administration: oculomucocutaneous syndrome. Br Med J. 1975 Mar 15;1(5958):595–598. doi: 10.1136/bmj.1.5958.595. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES